Skip to Content

AVITA Medical Inc AVH

Morningstar Rating
A$5.41 +0.18 (3.44%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

AVH is trading within a range we consider fairly valued.
Price
A$5.23
Fair Value
A$1.10
Uncertainty
Very High
1-Star Price
A$5.98
5-Star Price
A$4.50
Economic Moat
Gvcg
Capital Allocation
Smwhrpvn

Bulls Say, Bears Say

Bulls

We view Avita’s RECELL system as a sound alternative treatment for large second- and third-degree burns treated in burn centers. It compares favorably on price and ease of use with new products and the existing standard of care being skin grafts.

Bears

Avita is still burning cash and the road to profitability depends on clinical readouts for further indications over the next few years, with the use of RECELL currently limited to adult and paediatric patients at burn centers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
A$5.23
Day Range
A$5.345.44
52-Week Range
A$2.886.27
Bid/Ask
A$5.38 / A$5.41
Market Cap
A$694.08 Mil
Volume/Avg
62,797 / 212,060

Key Statistics

Price/Earnings (Normalized)
Price/Sales
8.77
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Growth
Total Number of Employees
207

Competitors

Valuation

Metric
AVH
NAN
COH
Price/Earnings (Normalized)
53.6160.55
Price/Book Value
9.124.7812.41
Price/Sales
8.775.1310.34
Price/Cash Flow
35.2351.66
Price/Earnings
AVH
NAN
COH

Financial Strength

Metric
AVH
NAN
COH
Quick Ratio
7.355.261.80
Current Ratio
7.886.562.57
Interest Coverage
−30.1012.4650.97
Quick Ratio
AVH
NAN
COH

Profitability

Metric
AVH
NAN
COH
Return on Assets (Normalized)
−37.61%9.04%14.09%
Return on Equity (Normalized)
−50.88%11.94%20.32%
Return on Invested Capital (Normalized)
−44.09%9.96%17.67%
Return on Assets
AVH
NAN
COH
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ABT
Abbott LaboratoriesQswvz$205.8 Bil
SYK
Stryker CorpSft$134.3 Bil
MDT
Medtronic PLCGfhg$111.0 Bil
BSX
Boston Scientific CorpSvbwkj$98.5 Bil
EW
Edwards Lifesciences CorpJxhklg$51.2 Bil
DXCM
DexCom IncXkxvy$46.9 Bil
ZBH
Zimmer Biomet Holdings IncKph$25.4 Bil
ALGN
Align Technology IncKqvhcm$22.5 Bil
PHG
Koninklijke Philips NV ADRWgxrvh$18.4 Bil
PODD
Insulet CorpMczvjr$11.8 Bil

Sponsor Center